Outcomes following treatment discontinuation in CML: real-world experience from 3 regional UK centres
Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
Colleges, School and Institutes
Emerging evidence from clinical trials has demonstrated the feasibility of TKI discontinuation in CML. However, real-world data of treatment discontinuation has been limited, particularly where this is due to clinical considerations such as drug toxicities. To address the real-world outcomes of treatment discontinuation and factors influencing this, we retrospectively analysed all patients from 3 hospitals in Birmingham, UK who have discontinued CML treatment since 2010.
|Title of host publication||HemaSphere|
|Publication status||Published - Jun 2019|